MINJUVI
As listed in the register: MINJUVI 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
200 mg · polvo para concentrado para solución para perfusión
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Tafasitamab
- Made by
- Incyte Biosciences Distribution B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
France1 matching products
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Incyte Biosciences Distribution B.V. |
|---|---|
| Active substance | Tafasitamab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg |
| Form | polvo para concentrado para solución para perfusión |
| Classification | L01FX12 · Cancer treatments and immune-system medicines |
| Route | vía intravenosa |
| Marketed | Yes, according to the register |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | MINJUVI 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION |
| Nº Registro | 1211570001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.